Profile data is unavailable for this security.
About the company
Bergenbio ASA is a Norway-based clinical-stage biopharmaceutical company focused on developing drugs for aggressive diseases including cancer and severe respiratory infections. The Company's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The Company's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.
- Revenue in NOK (TTM)354.00k
- Net income in NOK-190.40m
- Incorporated2008
- Employees18.00
- LocationBergenbio ASAMollendalsbakken 9BERGEN 5009NorwayNOR
- Phone+47 55961159
- Websitehttps://www.bergenbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ascelia Pharma AB | 0.00 | -109.90m | 399.20m | 13.00 | -- | 5.52 | -- | -- | -3.20 | -3.20 | 0.00 | 2.13 | 0.00 | -- | -- | 0.00 | -71.51 | -- | -85.53 | -- | -- | -- | -- | -- | -- | -- | 0.0141 | -- | -- | -- | 16.72 | -- | -- | -- |
| Lifecare AS | 13.09m | -35.26m | 412.69m | 32.00 | -- | 6.21 | -- | 31.54 | -0.2903 | -0.2903 | 0.1088 | 0.4924 | 0.1621 | -- | 4.90 | 408,943.10 | -43.60 | -40.00 | -49.97 | -45.26 | -- | -- | -269.03 | -175.53 | -- | -- | 0.1812 | -- | -40.88 | 30.29 | -101.74 | -- | -- | -- |
| INIFY Laboratories AB | 3.44m | -51.72m | 422.89m | 23.00 | -- | 5.75 | -- | 122.90 | -1.14 | -1.14 | 0.0761 | 1.63 | 0.032 | 2.99 | 0.6608 | -- | -48.10 | -- | -48.10 | -- | 76.42 | -- | -1,503.10 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Mendus AB (publ) | 0.00 | -102.19m | 480.57m | 30.00 | -- | 0.5812 | -- | -- | -0.2554 | -0.2554 | 0.00 | 0.8165 | 0.00 | -- | -- | 0.00 | -14.77 | -18.84 | -15.78 | -20.21 | -- | -- | -- | -28,474.53 | -- | -- | 0.0325 | -- | -100.00 | -- | 26.78 | -- | -- | -- |
| Initiator Pharma A/S | 0.00 | -35.92m | 488.97m | 3.00 | -- | 27.66 | -- | -- | -0.6573 | -0.6573 | 0.00 | 0.3322 | 0.00 | -- | -- | 0.00 | -58.55 | -65.10 | -62.50 | -70.59 | -- | -- | -- | -- | -- | -- | 0.5804 | -- | -- | -- | 40.52 | -- | -- | -- |
| Promimic AB | 37.28m | -9.27m | 545.95m | 17.00 | -- | 7.08 | -- | 14.65 | -0.5295 | -0.5295 | 2.08 | 4.11 | 0.3994 | -5.63 | 3.00 | 2,180,588.00 | -9.93 | -24.88 | -11.67 | -29.25 | 103.90 | 101.23 | -24.87 | -89.46 | 3.98 | -- | -- | -- | 128.63 | -- | 41.95 | -- | -- | -- |
| Bergenbio ASA | 354.00k | -190.40m | 556.60m | 18.00 | -- | 3.00 | -- | 1,572.32 | -0.2647 | -0.2647 | 0.0002 | 0.0474 | 0.0021 | -- | -- | -- | -111.66 | -66.15 | -176.09 | -78.74 | -- | -- | -53,785.59 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
| Enzymatica AB (publ) | 47.55m | -53.97m | 570.11m | 18.00 | -- | 6.76 | -- | 11.99 | -0.3247 | -0.3247 | 0.2866 | 0.4841 | 0.3269 | 1.38 | 6.48 | -- | -37.11 | -27.36 | -39.16 | -33.98 | 64.25 | 65.08 | -113.50 | -66.12 | -- | -23.26 | 0.2502 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| IRLAB Therapeutics AB | 5.71m | -178.83m | 570.24m | 37.00 | -- | 4.91 | -- | 99.87 | -3.43 | -3.43 | 0.1095 | 2.23 | 0.0227 | -- | 0.5137 | -- | -71.04 | -27.12 | -82.41 | -30.42 | -2,161.57 | -72.18 | -3,132.07 | -155.57 | -- | -- | 0.1923 | -- | -90.71 | 216.07 | -56.82 | -- | -22.56 | -- |
| Gentian Diagnostics ASA | 135.15m | -10.65m | 595.30m | 58.00 | -- | 4.06 | -- | 4.40 | -0.6905 | -0.6905 | 8.76 | 9.51 | 0.7329 | 1.76 | 7.47 | 2,330,224.00 | -5.77 | -10.76 | -6.62 | -11.86 | 50.61 | 41.46 | -7.88 | -26.99 | 4.13 | -- | 0.0817 | -- | 32.98 | 27.63 | 54.92 | -- | -4.92 | -- |
| Cantargia AB | 0.00 | -281.58m | 631.33m | 22.00 | -- | 3.72 | -- | -- | -1.65 | -1.65 | 0.00 | 0.9186 | 0.00 | -- | -- | 0.00 | -80.18 | -55.08 | -100.27 | -61.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.69 | -- | -- | -- |
| Oncopeptides AB | 35.42m | -250.50m | 632.35m | 57.00 | -- | 6.66 | -- | 17.86 | -1.96 | -1.96 | 0.2776 | 0.4474 | 0.1129 | -- | 1.44 | 617,894.80 | -79.88 | -141.28 | -101.04 | -200.49 | 103.06 | -- | -707.30 | -2,689.06 | -- | -- | 0.7065 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
| Orexo AB | 642.15m | -129.11m | 636.64m | 116.00 | -- | 10.67 | -- | 0.9914 | -3.73 | -3.73 | 18.55 | 1.71 | 0.6738 | 1.52 | 2.88 | 5,505,173.00 | -13.55 | -6.41 | -20.60 | -9.99 | 86.09 | 86.76 | -20.11 | -11.83 | 1.58 | 0.3604 | 0.8894 | -- | 2.32 | -3.99 | 27.76 | -- | 25.77 | -- |
| Alligator Bioscience AB | 58.43m | -249.97m | 698.99m | 58.00 | -- | 50.97 | -- | 11.96 | -0.5613 | -0.5613 | 0.1205 | 0.018 | 0.4035 | -- | 8.34 | 1,001,845.00 | -172.61 | -73.26 | -399.57 | -91.33 | -- | -- | -427.81 | -811.68 | -- | -- | 0.5759 | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
| Intellego Technologies AB | 187.53m | 59.94m | 755.23m | 68.00 | 12.06 | 4.97 | 11.90 | 4.03 | 2.36 | 2.36 | 7.43 | 5.74 | 0.8841 | 3.26 | 3.69 | 2,742,544.00 | 28.26 | -- | 44.00 | -- | 68.73 | -- | 31.96 | -- | 1.97 | 5.82 | 0.1684 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Bergenbio ASA's reporting currency: Norwegian Krone NOK
7.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| MP Pensjon PKas of 30 Sep 2023 | 57.07m | 2.12% |
| Nordnet Livsforsikring ASas of 16 Apr 2024 | 44.13m | 1.64% |
| Fj�rde AP-fondenas of 14 Jun 2023 | 39.11m | 1.46% |
| Handelsbanken Fonder ABas of 31 Mar 2024 | 32.52m | 1.21% |
| Storebrand Asset Management ASas of 31 Jan 2024 | 10.27m | 0.38% |
| Bergen Kommunale Pensjonskasseas of 16 Apr 2024 | 9.30m | 0.35% |
| KLP Kapitalforvaltning ASas of 25 Nov 2022 | 5.01m | 0.19% |
| Dimensional Fund Advisors LPas of 31 Jan 2024 | 659.85k | 0.03% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 36.57k | 0.00% |
More ▼
Data from 31 Dec 2023 - 03 May 2024Source: FactSet Research Systems Inc.
